Overview
Building on the accomplishments of DIA’s Regional Annual Meetings and on the collaborative initiatives developed in the Middle East region since 1996, the 1st edition of DIA Middle East will provide a key neutral platform to promote dialogue, drive collaboration and advance solutions amongst the key stakeholders in the region – from Health Authorities representatives to Industry leaders, Academia and Patients, among others.
DIA Middle East is the knowledge hub between science, healthcare, and regulation – and the place to meet trusted colleagues and make new connections with the brightest minds passionate about advancing health priorities in the region. With topics ranging from Regulatory Strategy and Convergence to Pharmacovigilance, Innovation and Clinical Development, DIA Middle East will provide a prime platform for constructive discussions and collaboration throughout the entire drug development lifecycle.

Program Committee
-
Sara Torgal, MPharm Global Regulatory Policy Lead
DIA, Switzerland -
Bandar Al Hammad, MPharm Chief Pharmacist, Regulatory Affairs Department
Saudi Food and Drug Authority (SFDA), Saudi Arabia -
Amira Deia Younes Director, Eastern Europe, Middle East & Africa (EEMEA) Global Regulatory Policy
MSD, United Arab Emirates -
Fadila Lakkis Regulatory Affairs, Intelligence & Communications Manager, Gulf
GSK, United Arab Emirates -
Inas Chehimi Head Regulatory Affairs - Middle East & North Africa
Novartis Pharma Services AG, United Arab Emirates -
Catherine Al Ashram VP Regulatory Affairs & PV, Latin America MEA and Russia
Organon, Jordan -
Abdulrahim Alyahya Director, Regulatory Policy & Government Affairs
Biogen, Saudi Arabia -
Ali Al Shibly Murad Regulatory Affairs Senior Specialist -Levant
MSD, Lebanon
Have an account?